Monthly Archives: July 2014

"Stem Cells Dr. Nathan Newman" - Sean Wroe Jeuness Global Distributor
Stem Cells are the future of health and beauty. Jeunesse Global is at the forefront of this incredible Stem Cell Technology. Sean Wroe is a Jeunesse Global Distributor leading the way. http://www.seanwroe...

By: Sean Wroe

See the original post here:
"Stem Cells Dr. Nathan Newman" - Sean Wroe Jeuness Global Distributor - Video

Emma #39;s Story
Jeanette and David Nucifora have three daughters. There were all born at Credit Valley Hospital in Mississauga. At birth, they chose to save the cord blood stem cells for all three girls. This...

By: Cells for Life

Go here to read the rest:
Emma's Story - Video

Renowned Israeli stem-cell researcher in Fairfield Aug. 6

By Cindy Mindell

Dr. Yaqub Hanna

A leading Israeli scientist who has pioneered groundbreaking stem-cell reprogamming research will discuss his work on Wednesday, Aug. 6 at Jewish Senior Services in Fairfield.

Together with a team of researchers at the Weizmann Institute of Science Department of Molecular Genetics in Rehovot, Israel, Dr. Jacob (Yaqub) Hanna has overcome a major roadblock in the use of human stem cells for medical purposes. Funded by a grant from the Israel Cancer Research Fund, their pioneering breakthrough was recently published in the peer-reviewed international science journal, Nature.

Its not only Hannas work that is note-worthy: the award-winning research scientist is a Palestinian living in Israel, a native of Kafr Rama in the Galilee and the son of two medical doctors.

Hanna earned a BS in medical sciences summa cum laude in 2001, an MS in microbiology and immunology in 2003, and a PhD-MD in immunology summa cum laude in 2007, all from the Hebrew University of Jerusalem, where he was among the top five percent of all Israeli medical-school graduates. After completing his PhD, Hanna decided to abandon clinical medicine and focus on research, and spent four years conducting postdoctoral research in the lab, part of the Whitehead Institute for Biomedical Research at MIT.

During his postdoctoral work, Hanna was the first non-American to receive a prestigious Novartis Fellowship from the Helen Hay Whitney Foundation. He joined the Weizmann Institute Department of Molecular Genetics upon his return to Israel in 2011. That year, he received the Clore Prize for distinguished new faculty at the Weizmann Institute and was accepted as a Yigal Alon Program Scholar for junior faculty in Israel. He is also the recipient of the Wolf Foundations Krill Prize for Excellence in Scientific Research and the 2013 Rappaport Prize in Biomedical Research.

Hanna has had to find a way to navigate between his personal and professional identities.

Read more:
Stem Cells: Promises and Reality

Surgeons at the University Hospital Southampton have designed the new procedure to coat damaged cartilage with stem cells taken from the hip If successful, it will regenerate the remaining tissue, creating a permanent 'like-for-like' replacement for the first time Cartilage is a tough tissue covering the surface of joints and enables bones to slide over one another, reducing friction and acting as a shock absorber

By Lizzie Parry

Published: 07:05 EST, 23 July 2014 | Updated: 07:21 EST, 23 July 2014

221 shares

11

View comments

Surgeons have designed a new operation which they hope could prevent the development of arthritis and extend sporting careers.

The procedure, which is currently being trialled at Southampton General Hospital, involves coating damaged cartilage with stem cells, taken from a patients own hip, and surgical glue.

If successful, it will regenerate the remaining tissue and create a permanent 'like-for-like' replacement for the first time.

Surgeons at University Hospital Southampton have pioneered a new operation to treat knee injuries, which they hope will extend sporting careers. Argentinian striker Luis Suarez had an operation to remove his damaged meniscus, part of the cartilage in the knee, prior to the World Cup

Read the original post:
New knee op using stem cells could stop arthritis and extend sporting careers

Contact Information

Available for logged-in reporters only

Newswise BOSTON July 24, 2014 Japanese biologist Shinya Yamanaka won a Nobel Prize in 2012 for discovering how to create induced pluripotent stem cells (iPSCs), cells derived from normal adult cells that have the ability to differentiate into almost any other kind of cells. Scientists at Joslin Diabetes Center now have created the first iPSCs that offer a human model of insulin resistance, a key driver of type 2 diabetes.

This is one of the very first studies of human iPSC models for type 2 diabetes, and it points out the power of this technology to look at the nature of diabetes, which is complex and may be different in different individuals, says C. Ronald Kahn, MD, Joslins Chief Academic Officer and the Mary K. Iacocca Professor of Medicine at Harvard Medical School.

Until now, scientists examining the causes and effects of insulin resistance have struggled with a general lack of human cell lines from tissues such as muscle, fat and liver that respond significantly to insulin, Kahn says. Studying insulin resistance as it progresses through pre-clinical stages of type 2 diabetes has been particularly challenging.

There have been no good human cell models to study insulin resistance, but such cells can now be made with iPSCs, says Kahn, co-senior author on a paper about the study published in the journal Diabetes.

Generation of iPSCs typically starts with fibroblasts (connective tissue cells) from skin samples. Kahn and his colleagues used fibroblasts from three patients with severe insulin resistance brought on by mutations in the gene for the insulin receptor (IR)a molecule that crosses the cell membrane and plays a key role in insulin signaling and glucose metabolism.

The Joslin researchers reprogrammed the fibroblasts into iPSCs by using viral procedures that activated four genes that together maintain cells in the iPSC state. The scientists then looked at gene activation in insulin signaling pathways for iPSCs and fibroblasts with IR mutations, and for corresponding cells derived from people without those mutations.

Among the study findings, IR mutations alter expression of many genes both in fibroblasts and iPSCs compared to normal cells, but the impact is very much dependent on the cell type, says Kahn. You see one type of expression pattern in the fibroblasts and a different type of pattern in the iPSCs.

Insulin is a key ingredient for the growth and proliferation of normal stem cells, and the study demonstrated that insulin resistance also reduces the ability of the iPSCs to grow and proliferate. That defect may represent a previously unrecognized mechanism that aids in developing diabetes, Kahn says, as well as helping to explain the problems in wound healing, tissue repair and even beta-cell growth that are common among people with diabetes.

View post:
Joslin Scientists Create the First IPS Cells to Offer Human Model of Insulin Resistance